Regulatory T cells (Treg cells) are a pivotal component of immune homeostasis. They suppress excessive immune responses and enforce self-tolerance using multiple immunosuppressive mechanisms that act via both contact-dependent and contact-independent pathways. Because of these properties, Treg cells have demonstrated substantial therapeutic potential across a spectrum of immune-mediated disorders and in several non-immune disease contexts. The review emphasizes the central role of Treg cells as modulators of immune responses and as a platform for cell-based therapeutic strategies.
The review systematically summarizes current approaches to induce and expand Treg cells. Major categories covered include:
Antigenic stimulation: directed exposure to antigens to promote Treg differentiation and antigen-specific suppressive functions.
Cytokine modulation: use of cytokine environments and signaling cues that favor Treg induction and maintenance.
Metabolic pathway manipulation: targeting metabolic programs that support Treg differentiation and function.
Epigenetic regulation: modifying chromatin and DNA methylation states to stabilize Treg lineage identity.
Drug induction: pharmacologic agents that promote Treg generation or enhance their suppressive activity.
Engineered technology: genetic or cellular engineering methods to create or enhance Treg cells with defined specificities or improved properties.
Each strategy carries inherent strengths; for example, antigenic stimulation can confer specificity, while engineered technologies can deliver target precision or functional enhancements. However, the authors note that singular strategies are limited in addressing the full set of challenges associated with therapeutic Treg use.
A central conclusion of the review is that no single induction approach comprehensively resolves key translational challenges. Critical issues include maintaining long-term Treg stability, achieving precise target specificity, and enabling large-scale, clinically practical production. To overcome these barriers, the authors propose integrating several induction modalities during the Treg generation process. Combining antigenic cues with cytokine conditioning, metabolic support, epigenetic stabilization, selective drugs, and engineering techniques may produce Treg cell products with superior functionality and wider therapeutic applicability. The review frames such multi-modal induction as a path toward next-generation Treg therapies that better meet clinical requirements.
The review outlines therapeutic areas within immune-mediated disease where Treg-based strategies have potential impact. These include:
Autoimmune diseases: leveraging Treg suppressive activity to restore tolerance and reduce pathological autoimmunity.
Organ transplantation: applying Treg therapies to limit graft rejection and reduce the need for broad immunosuppression.
Allergic asthma: employing Treg induction to dampen hyperactive allergic responses and airway inflammation.
Cancer: addressing the dual, context-dependent roles of Treg cells in tumor immunity and considering how engineered or targeted Treg modulation might be therapeutically relevant.
For each application area, the review discusses how different induction strategies could be prioritized depending on the need for antigen specificity, durability, or local tissue activity.
Beyond classic immune disorders, the authors describe several non-immune disease contexts where Treg cells show promise:
Insulin resistance: potential roles for Treg-mediated regulation of inflammation-linked metabolic dysfunction.
Tissue repair: Treg contributions to regenerative processes and wound healing through immunomodulatory and trophic effects.
Fibrotic diseases: modulating profibrotic inflammation and tissue remodeling via Treg activity.
Osteoporosis: interactions between immune regulation and bone metabolism that could be influenced by Treg-targeted approaches.
The review highlights that these applications expand the potential clinical footprint of Treg-based interventions and motivate diverse induction strategies tailored to non-immune tissue contexts.
The authors identify several ongoing bottlenecks in translating Treg biology into effective therapies. Key challenges include:
Ensuring durable lineage stability so that Treg cells maintain suppressive identity and do not convert to effector phenotypes.
Achieving target specificity to avoid generalized immune suppression and to focus activity on disease-relevant antigens or tissues.
Developing scalable manufacturing processes that produce clinical-grade Treg cell products at necessary yield and consistency.
Balancing the trade-offs between potency, safety, and manufacturability across different induction approaches.
To address these gaps, the review recommends integrated induction protocols that combine complementary strategies—antigenic, cytokine, metabolic, epigenetic, pharmacologic, and engineered—to create optimized Treg products. The authors provide an outlook that continued mechanistic research and technological development are needed to deepen understanding of Treg biology and accelerate advancement of Treg-based cellular therapeutic strategies.
This review synthesizes contemporary approaches to induce regulatory T cells and maps their potential applications across immune and non-immune diseases. It underscores that while individual induction strategies offer valuable tools, hybrid approaches are likely required to overcome critical translational hurdles such as stability, specificity, and production scale. The article aims to inform future research directions and the rational design of next-generation Treg therapies. The authors report no competing interests.